ClinicalTrials.gov
public full text
Public Domain
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers.#338503
- A microfluidic paper-based analytical device for early diagnosis and prognosis of acute myocardial infarction#1041666
- May Nesfatin-1 be a biomarker in Acute mesenteric ischemia?#955727
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD#863603
- Serum Albumin in Acute Coronary Syndrome#1075163
Record · ID 837454
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive